Business
Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced presentations including nonclinical data examining the renal
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high affinity antagonist of both endothelin type A (ETA) and angiotensin II type 1 (AT1) receptors, in focal segmental glomerulosclerosis (FSGS) mouse models, at the 58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress. The Company and its collaborators will also present analyses from independent randomized controlled studies and registries exploring the beneficial treatment effects of reducing proteinuria in FSGS and IgA nephropathy. ERA-EDTA is being held virtually June 5-8, 2021. Oral Presentations: Sparsentan improves glomerular blood flow and augments protective tissue remodeling in mouse models of focal segmental glomerulosclerosisPresentation #: MO1132Session Title: Pathology meets clinicsDate & Time: Monday, June 7, 2021, 17:00-18:30 CEST Estimating delay in time to ESKD for treatment effects on proteinuria in IgA nephropathy and FSGSPresentation #: MO246Session: Moderated Mini-Orals 2Date & Time: Sunday, June 6, 2021, 16:30-17:45 CEST The treatment effect of RAS blockade on proteinuria in IgA nephropathy patients as a surrogate for renal events and decline in eGFR: An analysis of randomized controlled trialsPresentation #: MO256Session: GlomerulonephritisDate & Time: Available beginning June 5, 2021 About Sparsentan Sparsentan is a novel investigational product candidate, that functions as a high affinity dual-acting antagonist of both the endothelin type A and angiotensin II type 1 receptors, in a single molecule. Pre-clinical data have shown that blockade of both pathways in forms of rare chronic kidney disease, reduces proteinuria, protects podocytes and prevents glomerulosclerosis and mesangial cell proliferation. Sparsentan has been granted Orphan Drug Designation for the treatment of IgAN and FSGS in the U.S. and Europe. Sparsentan is currently being evaluated in the pivotal Phase 3 DUPLEX Study for the treatment of focal segmental glomerulosclerosis (FSGS) and the pivotal Phase 3 PROTECT Study for the treatment of IgAN. In February 2021, the Company announced that the ongoing pivotal Phase 3 DUPLEX Study of sparsentan in FSGS achieved its pre-specified interim FSGS partial remi...